The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore. To date, the agency has authorized three batches for emergency use after reviewing facility records and results of quality testing performed by the manufacturer. 

“While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management,” FDA said.
 

Related News Articles

Headline
The AHA yesterday joined the U.S. Chamber of Commerce and American Medical Association in urging the 11th Circuit Court of Appeals to void a district court…
Headline
All clinicians should get vaccinated against COVID-19, encourage their staff and patients to get vaccinated, and recommend immunocompromised patients continue…
Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…